Literature DB >> 7606343

Bronchodilator and pre-protective effects of urodilatin in bovine bronchi in vitro: comparison with atrial natriuretic peptide.

J E Nally1, C C Docherty, R A Clayton, N C Thomson.   

Abstract

1. This study examined the activity and mechanisms of action of urodilatin in bovine bronchi. For comparison, the ability of urodilatin to evoke bronchodilatation or protect against subsequent challenge was compared to that of the closely related peptide alpha-human atrial natriuretic peptide (ANP). 2. Urodilatin reversed methacholine-evoked contraction in a concentration-dependent manner in bovine bronchi. In the absence of any attempt to prevent degradation by neutral endopeptidases, urodilatin was more potent than ANP in this tissue. 3. The bronchodilator properties of urodilatin were significantly augmented by the neutral endopeptidase inhibitor, phosphoramidon (3.68 x 10(-5) M). This provides evidence for at least partial degradation of urodilatin by neutral endopeptidases. With phosphoramidon present, urodilatin and ANP were equipotent. 4. In the presence of phosphoramidon (3.68 x 10(-5) M), pre-incubation with urodilatin (10(-6) M) had a protective effect against subsequent methacholine-induced contraction. This action of urodilatin was quantitatively similar to that of ANP in the presence of this endopeptidase inhibitor. 5. The actions of urodilatin appear to involve ATP-sensitive K+ channels since tolbutamide (10(-6) - 10(-5) M) significantly attenuated the relaxations induced by this peptide. 6. Small conductance Ca(2+)-activated K+ channels seem likewise to be implicated in the actions of urodilatin since blockade of these channels with apamin (10(-7) - 10(-6) M) resulted in a marked attenuation of urodilatin-evoked responses. 7. The presence of charybdotoxin (10-9 M-10-M) had no significant effect on subsequent responses tourodilatin suggesting that large conductance Ca2+-activated K+ channels are not involved in the relaxations evoked by this peptide.8. In the presence of phosphoramidon (3.68 x 10-5 M), urodilatin (10-6 M) evoked elevation of cyclic GMP levels within bovine bronchial tissue. Levels of cyclic GMP increased significantly within 5-10 s in response to this peptide and preceded the initiation of relaxant responses. Maximum increases in cyclic GMP levels were reached within 5 min; the time required for maximal relaxation evoked by this peptide.9. In conclusion, urodilatin, like ANP reversed and protected against, subsequent methacholine-induced bronchoconstriction; an action enhanced by the presence of phosphoramidon (3.68 x 1O-5 M).Associated with these actions of urodilatin was a rise in cyclic GMP levels as well as the opening of ATP-sensitive K+ and small conductance Ca2+-activated K+ channels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606343      PMCID: PMC1510287          DOI: 10.1111/j.1476-5381.1995.tb13360.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  The mechanism of cGMP-induced relaxation in vascular smooth muscle.

Authors:  L M Popescu; C Panoiu; M Hinescu; O Nutu
Journal:  Eur J Pharmacol       Date:  1985-01-08       Impact factor: 4.432

2.  Radioimmunoassay for cyclic nucleotides. II. Adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in mammalian tissues and body fluids.

Authors:  A L Steiner; A S Pagliara; L R Chase; D M Kipnis
Journal:  J Biol Chem       Date:  1972-02-25       Impact factor: 5.157

3.  Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor.

Authors:  E H Ohlstein; B A Berkowitz
Journal:  Hypertension       Date:  1985 Mar-Apr       Impact factor: 10.190

4.  Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11.

Authors:  A J Kenny; A Bourne; J Ingram
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

5.  Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma.

Authors:  R M Angus; M J McCallum; G Hulks; N C Thomson
Journal:  Am Rev Respir Dis       Date:  1993-05

6.  Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle.

Authors:  R J Winquist; E P Faison; S A Waldman; K Schwartz; F Murad; R M Rapoport
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

7.  Effect of inhaled atrial natriuretic peptide on methacholine induced bronchoconstriction in asthma.

Authors:  R M Angus; M J McCallum; N C Thomson
Journal:  Clin Exp Allergy       Date:  1994-08       Impact factor: 5.018

8.  Modulation of the effect of atrial natriuretic peptide in human and bovine bronchi by phosphoramidon.

Authors:  R M Angus; J E Nally; R McCall; L C Young; J C McGrath; N C Thomson
Journal:  Clin Sci (Lond)       Date:  1994-03       Impact factor: 6.124

9.  Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation.

Authors:  R E White; A B Lee; A D Shcherbatko; T M Lincoln; A Schonbrunn; D L Armstrong
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

10.  Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition.

Authors:  Z A Abassi; J Tate; S Hunsberger; H Klein; D Trachewsky; H R Keiser
Journal:  Am J Physiol       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.